This company has been marked as potentially delisted and may not be actively trading. NASDAQ:AKRX Akorn (AKRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Akorn Stock (NASDAQ:AKRX) 30 days 90 days 365 days Advanced Chart Get Akorn alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.09▼$0.3252-Week Range N/AVolume1.19 million shsAverage Volume9.60 million shsMarket Capitalization$3.60 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois. Read More Receive AKRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Akorn and its competitors with MarketBeat's FREE daily newsletter. Email Address AKRX Stock News HeadlinesAkorn Reaches New 52-Week High (AKRX)May 15, 2023 | thestreet.comCarlin Consumer Health Names Scott Chapman Chief Executive Officer - Business WireOctober 20, 2022 | businesswire.comThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.July 3 at 2:00 AM | Crypto Swap Profits (Ad)Veterinary Eye Care Market Size to record USD 788.78 Million Growth at a CAGR of 4.65% by 2026, Evolving Opportunities with Bausch Health Co Inc. And Akorn Operating Co. - Technavio - PR NewswireOctober 10, 2022 | prnewswire.comA small fund wagered that Elon Musk would be forced to buy Twitter—and made a killing by betting against the crowd - FortuneOctober 9, 2022 | fortune.comDiuretic Drugs Market to Record a CAGR of 5.44%, Increasing Incidence of Hypertension Among People to Drive Growth - Technavio - Yahoo FinanceSeptember 29, 2022 | finance.yahoo.comMoody's downgrades Akorn to Caa2; revises outlook to stable from positive - Moody'sSeptember 15, 2022 | moodys.comPrestige Consumer (PBH) Brands & E-commerce Strength Bode Well - NasdaqSeptember 2, 2022 | nasdaq.comSee More Headlines AKRX Stock Analysis - Frequently Asked Questions How were Akorn's earnings last quarter? Akorn, Inc. (NASDAQ:AKRX) released its earnings results on Monday, May, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.09) by $0.45. The firm had revenue of $204.69 million for the quarter, compared to the consensus estimate of $168.90 million. Akorn had a positive trailing twelve-month return on equity of 8.53% and a negative net margin of 55.64%. What other stocks do shareholders of Akorn own? Based on aggregate information from My MarketBeat watchlists, some other companies that Akorn investors own include Bristol Myers Squibb (BMY), Integrated Device Technology (IDTI), Skechers U.S.A. (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC) and Quantenna Communications (QTNA). Company Calendar Last Earnings5/11/2020Today7/03/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:AKRX CIK3116 Webwww.akorn.com Phone847-279-6100FaxN/AEmployees2,227Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$226.77 million Net Margins-55.64% Pretax MarginN/A Return on Equity8.53% Return on Assets1.31% Debt Debt-to-Equity Ratio0.09 Current Ratio0.50 Quick Ratio0.32 Sales & Book Value Annual Sales$682.43 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow0.19 Book Value$1.86 per share Price / BookN/AMiscellaneous Outstanding Shares133,152,000Free FloatN/AMarket Cap$3.60 million OptionableOptionable Beta0.95 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:AKRX) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Akorn, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Akorn With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.